Last updated: February 23, 2026
What is the drug associated with NDC 00143-9566?
NDC 00143-9566 corresponds to a formulation of Humulin R U-500 KwikPen, a concentrated insulin used to manage hyperglycemia in adults with diabetes mellitus who require high doses of insulin. It is manufactured by Eli Lilly and has gained significance due to its unique concentration and administration method.
Market Overview
Current Market Size
The insulin market, valued at approximately USD 25 billion in 2022, is segmented into rapid-acting, long-acting, biosynthetic human insulins, and other formulations. U-500 insulin accounts for an estimated 5-8% of total insulin prescriptions. The market's growth rate is around 8% annually, driven by rising global diabetes prevalence and increasing insulin treatment adoption.
Competitor Landscape
- Novo Nordisk's NovoLog U-100 and U-200
- Eli Lilly's Humulin U-500 and Humulin R
- Sanofi's (e.g., Lispro, Regular)
U-500 insulin offers a distinct market position because of its concentration, reducing injection volume and frequency in patients requiring high doses.
Distribution Channels
Key distribution channels include:
- Specialty pharmacies
- Retail pharmacies
- Hospital-based providers
Reimbursement policies significantly influence access, with Medicaid, Medicare, and private insurers covering most prescription costs.
Regulatory Status
U-500 insulin is approved by FDA for multiple indications, including:
- Diabetes Mellitus, poorly controlled with, or requiring, high-dose insulin therapy
- On-label uses include use in insulin pump therapy and multi-injection regimens
Its approval was initially granted in 1995, with recent updates to prescribing information in 2020 to improve safety protocols.
Price Trajectory Analysis
Current Pricing
- Wholesale Acquisition Cost (WAC): Approximately USD 275 per 10 mL vial for U-500 insulin (Eli Lilly)
- Average Sale Price (ASP): Estimated USD 245–260 per 10 mL vial
- Per unit cost: Roughly USD 0.098 per unit, compared to USD 0.025–0.035 for U-100 insulin
Price Drivers
- Concentration advantage
- Disposal and wastage reduction
- Packaging innovations (KwikPen)
- Regulatory updates and safety guidelines impacting manufacturing costs
- Market demand for high-dose formulations
Historical Price Trends
Between 2015 and 2022, the cost of U-500 insulin increased approximately 4-6% annually. Price increases have been slightly below the inflation rate but are influenced by supply chain dynamics, regulatory costs, and insurer negotiations.
Future Price Projections
Assuming current market trends persist, price adjustments are projected as follows:
| Year |
Predicted WAC per 10 mL vial |
Assumptions |
| 2023 |
USD 280 |
Slight inflation, no major regulatory or market disruptions |
| 2024 |
USD 290 |
Increased regulatory costs, inflationary pressures |
| 2025 |
USD 300 |
Stabilization of supply chain, continued demand growth |
The compound annual growth rate (CAGR) for WAC prices is expected to be approximately 3–4% over the next three years.
Market Access and Reimbursement Impact
Price increases may be moderated by insurer formulary restrictions and negotiations. Insurers increasingly favor biosimilars, though for U-500 insulin, no biosimilar options are currently approved, limiting competitive pressure.
Strategic Considerations
- Introductions of biosimilar high-concentration insulins could pressure pricing.
- Changes in regulatory policy regarding compounded insulin safety might influence manufacturing costs and pricing.
- Market expansion in emerging economies presents growth potential but also regulatory hurdles.
Key Takeaways
- The current U.S. wholesale price for NDC 00143-9566 is approximately USD 275 per 10 mL vial.
- The market is stable with moderate annual growth driven by rising diabetes prevalence.
- Price projections suggest a 3–4% increase annually over the next three years.
- Competitive pressures from biosimilars are absent since no biospecifics are currently available for U-500 insulin.
- Insurance coverage largely determines patient access and can influence pricing stability.
FAQs
What factors most influence U-500 insulin pricing?
Pricing is affected by formulation costs, regulatory compliance, supply chain logistics, and reimbursement negotiations.
How does U-500 insulin compare to U-100 in cost-effectiveness?
While U-500 insulin costs more per unit, it reduces injection volume and frequency, potentially lowering overall therapy costs and improving adherence.
Are biosimilars expected to impact U-500 insulin prices soon?
No biosimilar high-concentration insulins are approved presently; their development and approval would likely influence future pricing.
How might regulatory changes affect the market?
Enhanced safety regulation could increase manufacturing costs, potentially leading to higher prices, but could also improve confidence and coverage.
What markets outside the U.S. could influence future price trends?
Emerging markets may see growing adoption due to diabetes prevalence. Local regulatory and reimbursement policies will influence prices.
Citations
- IQVIA. (2022). Pharmaceutical Market Dynamics.
- FDA. (2020). Approval of Humulin R U-500 KwikPen.
- MarketWatch. (2022). Global Insulin Market Analysis.
- Centers for Medicare & Medicaid Services. (2023). Reimbursement Policies.
- Pharmaceutical Commerce. (2023). Price Trends in Insulin.
[1] IQVIA. (2022). Pharmaceutical Market Dynamics.
[2] U.S. Food and Drug Administration. (2020). Humulin R U-500 KwikPen approval.
[3] MarketWatch. (2022). Global Insulin Market Analysis.
[4] Centers for Medicare & Medicaid Services. (2023). Reimbursement Policies.
[5] Pharmaceutical Commerce. (2023). Price Trends in Insulin.
